Delcath Systems, Inc.

Equities

DCTH

US24661P8077

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
5.3 ^USD	+0.76%		+8.83%	+27.40%

Apr. 26	Delcath Systems Amends Supply, Manufacturing Agreement With Synerx Pharma, Mylan Teoranta for Melphalan Hydrochloride	MT
Mar. 27	HC Wainwright Adjusts Delcath Systems' Price Target to $20 From $18, Maintains Buy Rating	MT

Delcath Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 26, 2024 at 07:30 am EDT

Delcath Systems, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 0.539 million compared to USD 0.639 million a year ago. Net loss was USD 11.14 million compared to USD 8.47 million a year ago.

Basic loss per share from continuing operations was USD 0.48 compared to USD 0.86 a year ago.

Latest news about Delcath Systems, Inc.

Delcath Systems Amends Supply, Manufacturing Agreement With Synerx Pharma, Mylan Teoranta for Melphalan Hydrochloride	Apr. 26	MT
HC Wainwright Adjusts Delcath Systems' Price Target to $20 From $18, Maintains Buy Rating	Mar. 27	MT
Earnings Flash (DCTH) DELCATH SYSTEMS Reports Q4 Revenue $539,000, vs. Street Est of $550,000	Mar. 26	MT
Transcript : Delcath Systems, Inc., Q4 2023 Earnings Call, Mar 26, 2024	Mar. 26
Delcath Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Delcath Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 26	CI
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Delcath Systems, Inc. announced that it has received $7.00111 million in funding	Mar. 19	CI
Delcath Systems Names Chief Operating Officer	Mar. 19	MT
Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer	Mar. 18	CI
Delcath Systems, Inc. announced that it expects to receive $7.00111 million in funding	Mar. 14	CI
Delcath Systems, Inc. Announces Healthcare Setting Locator for HEPZATO? KIT (melphalan/Hepatic Delivery System)	Feb. 22	CI
Delcath Systems, Inc. Announces Executive Changes	Feb. 14	CI
Delcath Systems Receives Permanent J-Code for HEPZATO? (melphalan/Hepatic Delivery System) Effective April 1, 2024	Jan. 31	CI
Delcath Systems Launches Hepzato Kit in US for Treatment of Metastatic Uveal Melanoma	Jan. 16	MT
Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing Hepzato Kit?	Jan. 16	CI
Delcath Systems Insider Bought Shares Worth $148,800, According to a Recent SEC Filing	Nov. 20	MT
Transcript : Delcath Systems, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Earnings Flash (DCTH) DELCATH SYSTEMS Posts Q3 Revenue $434,000	Nov. 13	MT
Delcath Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Canaccord Genuity Adjusts Delcath Systems Price Target to $21 From $18, Maintains Buy Rating	23-09-07	MT
Delcath Systems Secures $35 Million Funding Linked to FDA Approval of HEPZATO KIT; Shares Rise	23-09-01	MT
Roth MKM Adjusts Price Target on Delcath Systems to $13 From $10, Maintains Buy Rating	23-08-16	MT
BTIG Adjusts Delcath Systems' Price Target to $20 From $19, Keeps Buy Rating	23-08-16	MT
HC Wainwright Adjusts Price Target on Delcath Systems to $18 From $17, Maintains Buy Rating	23-08-15	MT

Chart Delcath Systems, Inc.

Duration

Period

More charts

Company Profile

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Delcath Systems, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.3 USD

Average target price

19.75 USD

Spread / Average Target

+272.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Prosthetics

	1st Jan change	Capi.
DELCATH SYSTEMS, INC.	+27.40%	135M
STRAUMANN HOLDING AG	+1.84%	24.07B
SONOVA HOLDING AG	-6.34%	16.75B
DEMANT A/S	+10.34%	10.18B
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.	-17.75%	2.06B
EMBLA MEDICAL HF.	+6.38%	1.79B
ANGELALIGN TECHNOLOGY INC.	+41.47%	1.73B
MODERN DENTAL GROUP LIMITED	+13.26%	589M
ANGEL ROBOTICS CO., LTD.	0.00%	400M
INTEGRUM AB	+21.80%	93.49M

Medical Prosthetics